Therapeutics Company Receives FDA Designation For High-grade Glioma
Candel Therapeutics' CAN-3110: A New Hope for Recurrent High-Grade Glioma Patients.
Disclaimer: This post includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.
Candel Therapeutics Inc., a clinical-stage biotechnology company, has recently announced that their investigational drug, CAN-3110, has received Fast Track designation from the U.S. Food and Drug Administratio…